Abcuro gets $66M for Phase 3 in muscle-weakening condition
Endpoints News reports Abcuro raised $66M to advance its Phase 3 program in a muscle-weakening condition.
News Archive
Browse all past biotechnology intelligence, clinical developments, and industry updates.
Archived Updates
Biogen's monoclonal antibody felzartamab wins first global approval in China
Endpoints News reports Biogen's monoclonal antibody felzartamab received its first global approval in China.
Capricor, seeking lifeline for Duchenne therapy, says it will ask FDA to review additional data
Endpoints News reports Capricor Therapeutics plans to ask FDA to review additional data for its Duchenne muscular dystrophy therapy.
Cytokinetics brings patent suit against Bristol Myers, escalating rivalry
Endpoints News reports Cytokinetics filed a patent infringement lawsuit against Bristol Myers Squibb, escalating competition in the cardiac myosin modulator space.
Definium chalks up new phase 3 win for LSD-based therapy
Psychedelic drug developer Definium Therapeutics has reported positive phase 3 results with its LSD-based therapy DT120.
England close to eliminating hep C thanks to treatment drive
England is on track to be one of the first countries in the world to eliminate hepatitis C, thanks to a national diagnosis and treatment drive.
Exclusive: BioNTech vets get $25M seed funding for virtual cancer surveillance startup
Exclusive: BioNTech vets get $25M seed funding for virtual cancer surveillance startup
ICER says AstraZeneca’s new blood pressure med isn’t cost-effective
Endpoints News reports the Institute for Clinical and Economic Review (ICER) found AstraZeneca's new blood pressure medication not cost-effective at list price.
Lilly, PTC snap up bankrupt Sangamo's main assets
Just a few weeks after filing for bankruptcy protection, Sangamo has found buyers for some of its key assets, raising up to $85 million.
Novo Nordisk partners Amazon on London AI hub
Novo Nordisk has joined forces with Amazon Web Services (AWS) on a project that will lead to the creation of an AI co-innovation hub in London.
Redx tries again at reverse merger, with Skye this time, as alternative route gains steam
Endpoints News reports Redx Pharma is pursuing another reverse merger, this time with Skye Bioscience, as biotechs increasingly turn to alternative listing routes.
A genomics library for the AI era
Having spent 14 years building out its capacity, Regeneron Genetics Center—the genomic research branch of the Tarrytown, New York-based pharma—is a pro when it comes to the sort of target validatio | This week on "The Top Line," Fierce’s Fraiser Kansteiner sits down with Andy Deubler, chief business and administrative officer at Regeneron Genetics Center, to discuss the role RGC plays in the larger Regeneron model, as well as where the center could be headed as drug development pushes
ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial
/PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has approved ziresovir...
Aurisco Pharmaceutical est le premier fabricant mondial d'oligonucléotides génériques à avoir passé avec succès l'inspection de l'USFDA
Aurisco Pharmaceutical est le premier fabricant mondial d'oligonucléotides génériques à avoir passé avec succès l'inspection de l'USFDA
Bicara shakes up leadership ahead of CEO departure; J&J's John Reed joins Madrigal's board
Some big changes are coming at Bicara Therapeutics, and it starts at the top. President and COO Ryan Cohlhepp will take over as CEO on Jan. 1, and Claire Mazumdar will become vice chair.